Response_Letter_HTH-2023-32469.pdf
Response_Package_HTH-2023-32469.pdf
FOI Request - HTH-2023-32469 All documents from BC PharmaCare, such as internal documents, reports, and statistics outlining the number of patients approved for reimbursement for Nintedanib, or 'Ofev', for the treatment of Mild to Moderate Idiopathic Pulmonary Fibrosis ('IPF') and for the treatment of Chronic Fibrosing Interstitial Lung Diseases (ILDs) with a Progressive Phenotype also known as Progressive Fibrosing ILD (PF-ILD) or Progressive Pulmonary Fibrosis (PPF); all documents from BC PharmaCare, such as internal documents, reports, and statistics outlining the number of physicians requesting Nintedanib or 'Ofev', for the treatment of Mild to Moderate Idiopathic Pulmonary Fibrosis ('IPF') and for the treatment of Chronic Fibrosing Interstitial Lung Diseases (ILDs) with a Progressive Phenotype also known as Progressive Fibrosing ILD (PF-ILD) or Progressive Pulmonary Fibrosis (PPF); all documents from BC PharmaCare, such as internal documents, reports, and statistics outlining the reasons why approval for reimbursement was not granted for Nintedanib, or 'Ofev', for the treatment of Mild to Moderate Idiopathic Pulmonary Fibrosis ('IPF') and for the treatment of Chronic Fibrosing Interstitial Lung Diseases (ILDs) with a Progressive Phenotype also known as Progressive Fibrosing ILD (PF-ILD) or Progressive Pulmonary Fibrosis (PPF). (Date Range for Record Search: From 1/1/2021 To 9/1/2023) FOI Request FOI Request 2024-09-11 Health 9 2024 Response_Letter_HTH-2023-32469.pdf Response_Package_HTH-2023-32469.pdf Law Firm $30.00